ProCE Banner Activity

PURPOSE 2: Phase III Trial of Twice-Yearly LEN vs Daily FTC/TDF for HIV PrEP in Men and Transgender Women Who Have Sex With Men

Conference Coverage
Slideset

In phase III PURPOSE 2 study, twice-yearly subcutaneous lenacapavir was effective for PrEP among cisgender men, transgender women, transgender men, and gender-diverse individuals who are sexually active with partners assigned male at birth.

Released: October 15, 2024

Expiration: October 14, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner